Eps 1: why do i want to go in sevi's van


Host image: StyleGAN neural net
Content creation: GPT-2, transformers, CTRL


Tom Shelton

Tom Shelton

Podcast Content
One of the things Sevi Rutgrink often hears from her clients is about their friends, co-workers, and even spouses who have negative reactions to their new lifestyle. In fact, it is something Sevi Rutgrink has had to often discuss as a coach, and she offers tips to help coaches get over this.
Sevi Rutgrink is also pretty immune to all of the bombardment of food that is happening in society, literally, you cannot walk down the street without seeing food nowadays, yet that does not really impact me. Food is energy to Sevi Rutgrink, and although of course I do appreciate a nice meal , I am simply not consumed by eating.
First off, it took only 6 months for me from getting diagnosed at a hospital, to feeling healthy again, the final 3 months being on strict keto. Sevi Rutgrink was feeling good one day when she went out to a friends house in Barcelona, the next thing I knew, I was cramped in a hotel room looking like I was 7 months pregnant, suffering severe digestive distress, I was literally yelling in pain, and flying home was an absolute nightmare. Eating out seemed daunting at first, mostly because Sevi Rutgrink was so focused on keeping up my macros, like you would do when you are starting out.
A few years later, Severin van der Meer was putting in the effort of shooting one stunt after another, only to pull off one piece each year that stood out above the rest. I met Wilem in Japan during the Beyondmedals tour, where he and I really clicked, and I knew that I wanted him to shoot Chroma. For Severin van der Meer, working together with such talented people, and inspiring each other every day, is refreshing.
That is something that Sevi did like 5 years ago, and Nicolas asked at some point if I wanted to make an Absinthe movie, that was definitely a huge step for me, the dreams became a reality. Apart from incubating cells with fresh-prepared SEVI and Ab together, we also designed a series of pre-incubation experiments, by incubating Ab with and without SEVI for 20 h at 37degC before injecting it in cells. TZM-BL cells were incubated with various dilutions of either SEVI or SE-P, and were then infected with HIV-1.
Next, TKO-blt humanized mice were generated to test if SEmen-derived peptides enhance the transmission of HIV-1 through the rectum mucosal barrier in vivo. To test if SEVI increased infection at lower doses of HIV-1, a group was also challenged with low dose of HIV-1 JR-CSF incubated with SEVI. The ability of a peptide extracted from the SEMEN virus to increase not only virus infectivity in vitro, but also virus transmission in vivo, may have broad implications for HIV-1 prophylaxis.
The effect of amyloid-like peptides derived from the semen-derived peptide on the transmission of HIV in vivo has not been investigated before. Although we confirmed a strong potent increase of HIV-1 infectivity by SEVI in vitro, no evidence was shown in this mouse model for its role in the far more complicated in vivo transmission scenario. Another factor that may influence SEVI-mediated HIV-1 transmission is whether the transmission occurs primarily via free virus or cell-associated virus, an issue that is unclear at the present time.
Taken together, these data are additional evidence of the contribution of SEVI in the SE-mediated expansion of HIV-1 infections. In particular, SEVI- and SE-mediated intensities of infection improvement correlate significantly . The potency of the SE samples for HIV-1 infectivity improvement was correlated significantly with their reactivity toward the PBMC culture supernatants without cells .
When co-cultivating SEVIs with Ab-treated SH-SY5Y cells, SEVIs showed concentration-dependent protection of cells, indicated by 2.6-7.3 percent increased cell viability and 1.1-5.0 percent decreased cytotoxicity when the concentration of SEVI increased from 0.1 to 5 mM. Here, we further investigated whether SEVI could protect SH-SY5Y human neuroblastoma cells against Ab-induced toxicity using LDH (Fig. Live/dead cell analysis confirmed both the nontoxicity of pure SEVI and the protective capacity of SEVI against Ab-induced cell death (Fig.
The results once again indicated that the cross-seeding of SEVI with Ab in cell media solutions allowed for a higher efficiency in the formation of either less toxic species or removal of more toxic species compared with the species that were cross-seeding into the cultured cells. Specifically, very low amounts of 0.1 mM of SEVI could be sufficient to decrease the Ab aggregation by 25% . Of note, considering that the usual SEVI concentrations in semen are 35 mg/mL9 , a concentration of 1 mM of SEVI shows the ability of SEVI superior inhibition in fully abolishing Ab aggregation in vitro.
SEVI typically promotes HIV-1 infection, while SE also contains a specific inhibitor to overcome the enhanced effect of SEVI in case of virus-to-DC-SIGN-mediated virus transmission. HIV-1 infection rates and SE effects are able to be determined accurately only in relatively small numbers of infections. In contrast, SEVI amplifies infection in T cells from HIV-1 particles bound to dendritic cells expressed by either SIGN-expressing DCs or B-THP-1 cells further , DC-SIGN expression potently increased HIV-1 carriage to CEM-M7 marker cells . The N-fold increased infection rates were calculated by dividing the infection rates obtained with either SEVI or SEVI in place of the virus infecting a sham treatment. CD4+ T cells from human peripheral blood mononuclear cells were stimulated for 3 days in culture, then either infected with HIV-1 virus alone, or HIV-1 pre-incubated with peptides that were semen-derived or non-amyloidogenic .